Moon Jong Kim

US Patent:

6838556, Jan 4, 2005

Filed:

Jun 6, 2001

Appl. No.:

09/875453

Inventors:

Jungsuh P. Kim - Palo Alto CA, US
Douglas B. Starr - Mountain View CA, US
Albert W. Tam - San Francisco CA, US
Megan E. Laurance - San Francisco CA, US
Emil F. Michelotti - Foster City CA, US
Mark D. Velligan - Montara CA, US
Derek R. Latour - Hayward CA, US
Rita L. Thomas - San Jose CA, US
Ana Kongpachith - Union City CA, US
Liana T. Sheppard - Redwood City CA, US
Moon Young Kim - Redwood City CA, US
Thomas W. Bruice - Carlsbad CA, US

Assignee:

Genelabs Technologies, Inc. - Redwood City CA

International Classification:

C12N 1511

US Classification:

536 241

Abstract:

This invention provides nucleic acid sequences, vectors and host cells comprising regulatory regions associated with various promoters including a cyclin D1 promoter, a CD40L promoter, three HBV promoters (core, pre-S1 and HBV-X), a vancomycin-resistant enterococci (VRE) promoter, an androgen receptor promoter, a Her2 promoter, and β-lactamase promoter. The invention further provides methods of regulating gene expression comprising the regulatory regions of such promoters.

US Patent:

6973229, Dec 6, 2005

Filed:

Feb 28, 2001

Appl. No.:

09/795950

Inventors:

Anastasios Tzathas - Howell NJ, US
Moon W. Kim - Pleasanton CA, US
Abdella Battou - Silver Spring MD, US

Assignee:

Lambda OpticalSystems Corporation - Reston VA

International Classification:

G02B006/26
G02B006/28
H04J014/00

US Classification:

385 16, 385 17, 385 24, 398 43, 398 45, 398 48

Abstract:

An optical transport switching system having an all-optical switch that can be selectively configured to provide cross-connection and add/drop multiplexing functions. Optical circuit cards are provided in a chassis/bay, and connected by an optical backplane. The circuit cards may include access line interface cards, optical access ingress cards, transport ingress cards, transport egress cards, and optical access egress cards. An optical switching fabric provides selective optical coupling between the cards. The all-optical switch can be used in an optical network that allows external/access networks to access the optical network, including access networks that use Gigabit Ethernet or SONET signaling. Wavelength conversion is provided for non-compliant wavelengths of the access networks. A local area network enables control and monitoring of the cards by a local node manager.

US Patent:

7013084, Mar 14, 2006

Filed:

Feb 28, 2001

Appl. No.:

09/795252

Inventors:

Abdella Battou - Silver Spring MD, US
Moon W. Kim - Pleasanton CA, US
Anastasios Tzathas - Howell NJ, US
David H. Walters - Rockville MD, US
Mario F. Alvarez - Beachwood NJ, US
David M. Brooks - Crofton MD, US
I. Michael Mandelberg - Baltimore MD, US
Chin J. Chen - Rockville MD, US

Assignee:

Lambda OpticalSystems Corporation - Reston VA

International Classification:

H04J 14/00

US Classification:

398 45, 398 50, 398 51, 398 54, 398 56

Abstract:

A hierarchical and distributed control architecture for managing an optical communications network. The architecture includes a line card manager level for managing individual line cards in an optical switch, a node manager level for managing multiple line cards in an optical switch/node, and a network management system level for managing multiple optical switches/nodes in a network. An event manager at the node manager level enables software components that are running at the node manager to register for and receive events, and to post events. The events may be triggered, e. g. , by a change in a status of the switch, or an alarm condition. Control architecture functionalities include signaling, routing, protection switching and network management. Furthermore, the network management function includes a topology manager, a performance manager, a connection manager, a fault detection manager, and a configuration manager.

US Patent:

7498358, Mar 3, 2009

Filed:

Dec 13, 2002

Appl. No.:

10/498338

Inventors:

S. David Brown - San Carlos CA, US
Erick Wang Co - Redwood City CA, US
Vasu Jammalamadaka - Pleasonton CA, US
Rickard George Khoury - Redwood City CA, US
Moon Hwan Kim - Palo Alto CA, US
Donna T. Le - San Jose CA, US
Amy Lew Tsuhako - Milpitas CA, US
Morrison B. Mac - San Francisco CA, US
John M. Nuss - Danville CA, US
Michael P. Prisbylla - Pleasant Hill CA, US
Wei Xu - Danville CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

C07C 311/19
C07C 311/29
C07C 259/06
C07C 259/08
C07D 213/32
C07D 213/68
A61K 31/16
A61K 31/44
A61P 19/02
A61P 35/00
A61P 9/10

US Classification:

514507, 562621, 562623, 564 80, 560 12, 5462721, 5462834, 514351, 514357, 514518, 514562

Abstract:

The present invention provides compounds useful for inhibiting the ADAM-10 protein. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role. The invention also provides methods for making bis-aryl ether sulfonyl chlorides and ADAM-10 modulators therefrom.

US Patent:

7626031, Dec 1, 2009

Filed:

Nov 14, 2003

Appl. No.:

10/533555

Inventors:

Wei Xu - Danville CA, US
Erick Wang Co - Redwood City CA, US
John M. Nuss - Danville CA, US
Moon Hwan Kim - Palo Alto CA, US
Rhett Ronald Klein - San Francisco CA, US
Donna Tra Le - San Jose CA, US
Amy Lew Tsuhako - Milpitas CA, US
Jason Jevious Parks - Sacramento CA, US
Zhaoyang Wen - San Francisco CA, US
Wei Cheng - San Jose CA, US

Assignee:

Symphony Evolution, Inc. - Rockville MD

International Classification:

C07D 401/00
A61K 31/445

US Classification:

546196, 514320

Abstract:

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides oxindole derivatives which inhibit, regulate and/or modulate kinase receptor, particularly VEGF receptor 2 (Flk-1/KDR), FGFR1, and PDGFR (alpha and beta), signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.

US Patent:

7951972, May 31, 2011

Filed:

Feb 2, 2009

Appl. No.:

12/322422

Inventors:

S. David Brown - San Carlos CA, US
Erick Wang Co - Redwood City CA, US
Vasu Jammalamadaka - Pleasonton CA, US
Rickard George Khoury - Redwood City CA, US
Moon Hwan Kim - Palo Alto CA, US
Donna T. Le - San Jose CA, US
Amy Lew Tsuhako - Milpitas CA, US
Morrison B. Mac - San Francisco CA, US
John M. Nuss - Danville CA, US
Michael P. Prisbylla - Pleasant Hill CA, US
Wei Xu - Danville CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

C07C 311/19
C07C 311/29
C07C 259/06
C07C 259/08
C07D 213/32
C07D 213/68
A61K 31/16
A61K 31/44
A61P 19/02
A61P 35/00
A61P 9/10

US Classification:

562621, 514507, 514351, 514357, 514518, 514562, 562623, 564 80

Abstract:

The present invention provides compounds useful for inhibiting the ADAM-10 protein. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role. The invention also provides methods for making bis-aryl ether sulfonyl chlorides and ADAM-10 modulators therefrom.

US Patent:

8076338, Dec 13, 2011

Filed:

Apr 22, 2005

Appl. No.:

11/568173

Inventors:

Neel K. Anand - Burlingame CA, US
Charles M. Blazey - San Francisco CA, US
Owen Joseph Bowles - Pacifica CA, US
Joerg Bussenius - Foster City CA, US
Lynne Canne Bannen - Pacifica CA, US
Diva Sze-Ming Chan - San Francisco CA, US
Baili Chen - Palo Alto CA, US
Erick Wang Co - San Diego CA, US
Simona Costanzo - Los Altos CA, US
Steven Charles Defina - Burlingame CA, US
Larisa Dubenko - San Francisco CA, US
Maurizio Franzini - San Francisco CA, US
Ping Huang - Mountain View CA, US
Vasu Jammalamadaka - Pleasonton CA, US
Richard George Khoury - Redwood City CA, US
Moon Hwan Kim - Palo Alto CA, US
Rhett Ronald Klein - Chicago IL, US
Donna Tra Le - San Jose CA, US
Morrison B. Mac - San Francisco CA, US
John M. Nuss - Danville CA, US
Jason Jevious Parks - Sacramento CA, US
Kenneth D. Rice - San Rafael CA, US
Tsze H. Tsang - El Cerrito CA, US
Amy Lew Tsuhako - Milpitas CA, US
Yong Wang - Foster City CA, US
Wei Xu - Danville CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

A61K 31/501
A61K 31/497
C07D 473/16
C07D 401/04

US Classification:

51425202, 51425216, 544277, 544238, 544363

Abstract:

The present invention relates to compounds of the Formula (I) and (II) wherein R, R, R-R, m, n, X-X, and Qare defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or Akt kinases. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention.

US Patent:

8242129, Aug 14, 2012

Filed:

Apr 25, 2008

Appl. No.:

12/597275

Inventors:

Amy L. Tsuhako - Milpitas CA, US
Naing Aay - San Mateo CA, US
S. David Brown - San Carlos CA, US
Wai Ki Vicky Chan - San Francisco CA, US
Hongwang Du - Millbrae CA, US
Ping Huang - Mountain View CA, US
Brian Kane - Lynchburg VA, US
Patrick Kearney - San Francisco CA, US
Moon Hwan Kim - Palo Alto CA, US
Elena S. Koltun - Foster City CA, US
Michael Pack - San Francisco CA, US
Wei Xu - Danville CA, US
Peiwen Zhou - Palo Alto CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

A61K 31/505

US Classification:

514274, 544309, 544310, 544316, 544317

Abstract:

A compound having Formula I or II (Formula I) or (Formula II), or a pharmaceutically acceptable salt thereof, wherein X, Z, R, R, Rand Rare as defined in the specification; pharmaceutical compositions thereof; and methods of use thereof.

Address:

1418 E Hacienda Ave APT D, Las Vegas, NV 89119

VIN:

JH2RC444X7M101351

Make:

Chevrolet

Model:

Geo Tracker 2dr Hardtop

Year:

2007